Literature DB >> 2190134

Best's vitelliform dystrophy.

C F Blodi1, E M Stone.   

Abstract

Best's vitelliform dystrophy is an autosomal dominant disease that pathologically affects the retinal pigment epithelium and symmetrically affects the macula of patients at a very young age. Visual acuity tends to remain quite good for long periods of time. In the later stages of the disease, atrophic changes of the retinal pigment epithelium or scarring secondary to subretinal neovascular membranes with hemorrhage may cause a loss of central visual acuity. An abnormal diminished light to dark ratio of the electrooculogram is the hallmark of the disease. No other significant ocular abnormalities or systemic problems have been associated with this genetic disorder. No therapy exists for halting the progression of the disease with the possible exception of laser photocoagulation treatment used to ablate subretinal neovascular membranes in an attempt to avoid complications of subretinal hemorrhages. However, an accurate diagnosis and pedigree analysis is important for allowing the physician to perform adequate family and genetic counseling to affected patients.

Entities:  

Mesh:

Year:  1990        PMID: 2190134

Source DB:  PubMed          Journal:  Ophthalmic Paediatr Genet        ISSN: 0167-6784


  31 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

2.  [Best's disease with normal EOG. Case report of familial macular dystrophy].

Authors:  K Pollack; F R Kreuz; L E Pillunat
Journal:  Ophthalmologe       Date:  2005-09       Impact factor: 1.059

3.  In vivo dark-field imaging of the retinal pigment epithelium cell mosaic.

Authors:  Drew Scoles; Yusufu N Sulai; Alfredo Dubra
Journal:  Biomed Opt Express       Date:  2013-08-23       Impact factor: 3.732

Review 4.  Molecular genetics of macular dystrophies.

Authors:  K Zhang; H Yeon; M Han; L A Donoso
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

5.  A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy.

Authors:  L Zhao; S Grob; R Corey; M Krupa; J Luo; H Du; C Lee; G Hughes; J Lee; J Quach; J Zhu; P X Shaw; I Kozak; K Zhang
Journal:  Eye (Lond)       Date:  2012-03-16       Impact factor: 3.775

6.  Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration.

Authors:  Mary A Dwyer; Dmitri Kazmin; Peng Hu; Donald P McDonnell; Goldis Malek
Journal:  Mol Endocrinol       Date:  2011-01-14

7.  Suppression of Ca2+ signaling in a mouse model of Best disease.

Authors:  Youwen Zhang; J Brett Stanton; Jiang Wu; Kuai Yu; H Criss Hartzell; Neal S Peachey; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

8.  A model of best vitelliform macular dystrophy in rats.

Authors:  Alan D Marmorstein; J Brett Stanton; John Yocom; Benjamin Bakall; Marc T Schiavone; Claes Wadelius; Lihua Y Marmorstein; Neal S Peachey
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-10       Impact factor: 4.799

9.  Late-onset autosomal dominant macular dystrophy with choroidal neovascularization and nonexudative maculopathy associated with mutation in the RDS gene.

Authors:  Shahrokh C Khani; Athanasios J Karoukis; Joyce E Young; Rajesh Ambasudhan; Tracy Burch; Richard Stockton; Richard Alan Lewis; Lori S Sullivan; Stephen P Daiger; Elias Reichel; Radha Ayyagari
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

10.  Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Rossana Santacroce; Maurizio Margaglione; Nathalie Delphin; Jean-Michel Rozet; Josseline Kaplan; Domenico Martinelli; Nicola Delle Noci; Gisèle Soubrane; Eric H Souied
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.